MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.190
-0.070
-1.64%
After Hours: 4.250 +0.06 +1.43% 19:59 12/04 EST
OPEN
4.270
PREV CLOSE
4.260
HIGH
4.310
LOW
4.170
VOLUME
172.40K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
2.210
MARKET CAP
39.06M
P/E (TTM)
-1.5806
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment
ARCA Biopharma (ABIO) jumped 5.5% in today's trade for its highest close in a month after saying it received Fast Track designation from the U.S. Food and Drug Administration for
Seekingalpha · 11/24 03:15
ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment
Shares of ARCA Biopharma Inc. undefined gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug...
MarketWatch · 11/23 17:28
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020, with topline trial data anticipated in the second quarter of 2021.
GlobeNewswire · 11/23 13:30
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
GlobeNewswire · 11/23 13:30
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results for the third quarter of 2020 and provided a corporate update.
GlobeNewswire · 11/02 13:30
Ocular Therapeutix and American Well among healthcare gainers, ARCA biopharma and Axovant Gene Therapies among losers
Gainers: Taiwan Liposome (TLC) +36%. Ocular Therapeutix (OCUL) +21%. LogicBio Therapeutics (LOGC) +11%. American Well (AMWL) +11%. Tiziana Life Sciences (TLSA) +11%.Losers: Enlivex Therapeutics (ENLV) -12%. Aytu BioScience (AYTU) -12%. Xtant Medical (XTNT) -11%.
Seekingalpha · 10/07 14:54
ARCA biopharma on go with mid-stage study for AB201 in COVID-19
ARCA Biopharma (ABIO) 6% in premarket, as the FDA has signed off its Phase 2b/3 sequential trial evaluating AB201 (rNAPc2) as a potential treatment for patients hospitalized with COVID-19.The company plans to commence the
Seekingalpha · 10/07 12:55
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
-- Initiation of Phase 2b clinical trial anticipated in Q4 2020
GlobeNewswire · 10/07 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABIO. Analyze the recent business situations of ARCA BIOPHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 549.09K
% Owned: 5.89%
Shares Outstanding: 9.32M
TypeInstitutionsShares
Increased
3
287.34K
New
9
33.00K
Decreased
2
43.98K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.71%
Key Executives
Chairman/Director
Robert Conway
Chief Executive Officer/President/Director
Michael Bristow
Chief Operating Officer
Thomas Keuer
Senior Vice President/General Counsel/Secretary
Christopher Ozeroff
Chief Accounting Officer/Vice President - Finance
Brian Selby
Lead Director
Linda Grais
Director
Anders Hove
Director
Daniel Mitchell
Director
Raymond Woosley
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.